Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Renhuang Pharmaceuticals, a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines, has signed a research cooperation agreement with the College of Pharmacy, Harbin University of Commerce to jointly pursue extraction of effective parts from Siberian Ginseng (Acanthopanax).
Subscribe to our email newsletter
Siberian Ginseng is a plant found in the northern hemisphere in eastern Asia with demonstrated powerful anti-depression and anti-anxiety properties without the side effects associated with chemical drugs. Renhuang is a producer of Siberian Ginseng-based products and controls about 70% of China’s Siberian Ginseng resources.
As per the terms of the research agreement, Harbin University of Commerce is expected to be responsible for the research and development of preparation methods, including maintaining the stability of extracts, using the Korean Ginseng technical standards.
However, Renhuang will be responsible for improving the Siberian Ginseng-based products’ quality, carrying out pilot production, and implementing full-scale production.
Shaoming Li, chairman and CEO of Renhuang Pharmaceuticals, said: “Harbin University of Commerce is one of China’s premier research institutions and we are very pleased to announce our collaborative Research Agreement with its College of Pharmacy.
“This collaboration with Harbin University of Commerce reinforces Renhuang’s continued commitment to achieve excellence in research and development and expand our leadership position in Siberian Ginseng-based products, which will drive our future revenue growth.”